Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Perspective Therapeutics, Inc. (NYSE: CATX) had its price target lowered by analysts at Truist Financial Co. from $21.00 to $10.00. They now have a "buy" rating on the stock.
Perspective Therapeutics, Inc. (NYSE: CATX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Perspective Therapeutics to Participate in Upcoming April Investor Conferences
Perspective Therapeutics, Inc. (NYSE: CATX) had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $15.00. They now have an "outperform" rating on the stock.